Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.

Trial Details

NCT ID

NCT03257033

Phase

PHASE3

Sponsor

RenovoRx

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Gemcitabine
nab-paclitaxel
RenovoCath

Locations (sample)

Loma Linda, California, United States|34.04835,-117.26115
Sacramento, California, United States|38.58157,-121.4944
Denver, Colorado, United States|39.73915,-104.9847
Englewood, Colorado, United States|39.64777,-104.98776
Washington D.C., District of Columbia, United States|38.89511,-77.03637

Key Eligibility Criteria

Histologically or Cytopathology confirmed pancreatic adenocarcinoma with initial diagnosis within 8 weeks of consent for patients who enroll at cyc…
Locally advanced, unresectable disease at screening and prior to randomization, as defined by NCCN criteria determined by an on-site, experienced, …
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1
Age ≥ 18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →